Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays

Qun Yan, Melissa J. Karau, Yash S. Raval, Robin Patel

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

The antibiofilm activity of oritavancin in combination with rifampin, gentamicin, or linezolid was evaluated against 10 prosthetic joint infection (PJI)- related methicillin-resistant Staphylococcus aureus (MRSA) isolates by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared with those of either antimicrobial alone for all 10 isolates (P ≤ 0.001), with synergy being observed for 80% of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.

Original languageEnglish (US)
Article numbere00943
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number10
DOIs
StatePublished - Oct 2018

Keywords

  • Biofilm
  • Gentamicin
  • Linezolid
  • Methicillin-resistant Staphylococcus aureus
  • Oritavancin
  • Rifampin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays'. Together they form a unique fingerprint.

  • Cite this